Some people continue to have serious symptoms long after COVID-19, such as extreme fatigue and feeling worse after activity. In some patients, this may happen because the immune system is attacking the body by mistake.
Official registry: https://clinicaltrials.gov/study/NCT07316127 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · enrollment listed as 70
Phase 2: researchers already know a roughly safe dose (from phase 1). This stage asks whether the treatment actually helps the condition, and watches side effects more closely.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
If you join, the listed intervention(s) are Immunoadsorption, or Sham Comparator. The registry lists allocation as randomized. Some people continue to have serious symptoms long after COVID-19, such as extreme fatigue and feeling worse after activity.
They plan to enroll about 70 people at Amsterdam. Taking part typically means using or being fitted with a device plus check-ins.
A Placebo-Controlled, Double-Blind, Randomized Trial Phase I-II With Immunoadsorption in Autoimmune Long COVID
Interventions: Immunoadsorption, Sham Comparator
Primary outcome (registry wording): Change in fatigue measured by the Fatigue Assessment Scale (FAS)
Daphne Schouten, MD
postcovidtrials@amsterdamumc.nl
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
LIINC is a study of volunteers who were previously infected with SARS-CoV-2 (also known as novel coronavirus or COVID-19) who have recovered from acute infection. The study is designed to provide a specimen bank of samples with carefully characterized clinical data.
NCT04362150 · Official ClinicalTrials.gov record · University of California, San Francisco
We will enroll long-COVID patients with cognitive impairments. All patients will receive DAOIB for 24 weeks.
NCT05764538 · Official ClinicalTrials.gov record · Chang Gung Memorial Hospital
This study aims to verify the how well it works/effectiveness of treatment with transcranial direct current stimulation (TDCS) in patients with Long Covid who experience headaches, migraines, and chronic pain, such as arthralgia and myalgia, as well as sleep problems. Transcranial direct current stimulation is used in the field of Physiotherapy and Rehabilitation, with results that have proven to be effective for treating patients suffering from symptoms like migraines, headaches, chronic pain, fibromyalgia, or chronic neuropathic pain and insomnia.
NCT05780450 · Official ClinicalTrials.gov record · Fundación Universidad Católica de Valencia San Vicente Mártir
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary